Holen Sie sich die Stockscreener-App
2.44
2.52%
0.06
Handel nachbörslich:
2.48
0.04
+1.64%
Schlusskurs vom Vortag:
$2.38
Offen:
$2.42
24-Stunden-Volumen:
791.32K
Relative Volume:
0.55
Marktkapitalisierung:
$394.07M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-54.70M
KGV:
-7.3939
EPS:
-0.33
Netto-Cashflow:
$-51.36M
1W Leistung:
+7.02%
1M Leistung:
-18.67%
6M Leistung:
-34.41%
1J Leistung:
-39.30%
1-Tages-Spanne:
$2.35
$2.54
1-Wochen-Bereich:
$2.30
$2.55
52-Wochen-Spanne:
$1.89
$5.11
Savara Inc Stock (SVRA) Company Profile
Firmenname
Savara Inc
Sektor
Branche
Telefon
51285113796
Adresse
6836 BEE CAVE ROAD, AUSTIN, TX
Vergleichen Sie SVRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.44 | 394.07M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-13 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-11-07 | Eingeleitet | Guggenheim | Buy |
| 2023-05-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2021-03-16 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-15 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-13 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Fortgesetzt | ROTH Capital | Neutral |
| 2018-01-03 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-09-27 | Fortgesetzt | ROTH Capital | Buy |
| 2017-09-22 | Eingeleitet | Jefferies | Buy |
| 2017-09-11 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Savara Inc Aktie (SVRA) Neueste Nachrichten
savara elects board members and approves proposals at annual meeting - Investing.com Australia
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc.SVRA - PR Newswire
Savara Re-elects Board Members at Annual Meeting - TipRanks
Savara Inc (NASDAQ:SVRA) Shares Bought by Squarepoint Ops LLC - Defense World
FDA Requests Additional Data for Savara’s MOLBREEVI Application - MSN
Savara assumed with an Outperform at Oppenheimer - MSN
Nuveen Asset Management LLC Sells 30,766 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 - MSN
Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Bought by ProShare Advisors LLC - Defense World
Insider Buying Alert: Joseph Mccracken Acquires Additional Shares of Savara Inc (SVRA) - GuruFocus
Oppenheimer assumes Savara stock at outperform, sets $5 price target - Investing.com
Oppenheimer assumes Savara stock at outperform, sets $5 price target By Investing.com - Investing.com Canada
Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating - marketscreener.com
Oppenheimer Maintains Optimism for Savara (SVRA) Despite Filing Setback | SVRA Stock News - GuruFocus
Savara director Joseph McCracken buys $20,825 in stock By Investing.com - Investing.com South Africa
Savara director Joseph McCracken buys $20,825 in stock - Investing.com Australia
What is HC Wainwright’s Forecast for Savara FY2026 Earnings? - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is HC Wainwright’s Forecast for Savara FY2029 Earnings? - Defense World
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - BUCKSCO.Today
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Savara (NASDAQ:SVRA) Lowered to “Neutral” Rating by HC Wainwright - Defense World
Savara Inc. Grants Equity Awards to New Employees - MSN
SVRA: Savara Downgraded by HC Wainwright & Co. | SVRA Stock News - GuruFocus
Savara stock rating cut to Neutral by H.C. Wainwright - Investing.com Nigeria
HC Wainwright & Co. Downgrades Savara (SVRA) - MSN
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6 - marketscreener.com
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setba - GuruFocus
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setback | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI By Investing.com - Investing.com Canada
Savara Inc (NASDAQ:SVRA) Shares Bought by D. E. Shaw & Co. Inc. - Defense World
Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Given New $2.00 Price Target at Evercore ISI - Defense World
Savara (NASDAQ:SVRA) Price Target Lowered to $7.00 at Wells Fargo & Company - Defense World
SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Key Analyst Rating Update for Savara (SVRA) | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI - Investing.com Australia
Savara (SVRA) Stock Rating Maintained, Price Target Adjusted | S - GuruFocus
FDA refuses to file Savara BLA for Molbreevi - The Pharma Letter
Wells Fargo Maintains Overweight Rating on Savara (SVRA) with Lower Price Target | SVRA Stock News - GuruFocus
Savara (SVRA) Faces Lowered Price Target Amid BLA Challenges | S - GuruFocus
Savara (SVRA) Faces Lowered Price Target Amid BLA Challenges | SVRA Stock News - GuruFocus
Guggenheim cuts Savara stock target to $8, maintains Buy rating - Investing.com India
Guggenheim cuts Savara stock target to $8, maintains Buy rating By Investing.com - Investing.com South Africa
Savara Inc (NASDAQ:SVRA) Shares Purchased by BNP Paribas Financial Markets - Defense World
Finanzdaten der Savara Inc-Aktie (SVRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Savara Inc-Aktie (SVRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RAMSAY DAVID A | Director |
Mar 31 '25 |
Buy |
2.77 |
150,000 |
416,250 |
2,513,642 |
| Lowrance David L | Chief Financial Officer |
Dec 16 '24 |
Sale |
3.33 |
25,000 |
83,278 |
381,005 |
| Pauls Matthew | CHIEF EXECUTIVE OFFICER |
Dec 16 '24 |
Sale |
3.31 |
54,702 |
180,828 |
1,536,379 |
| Hawkins Richard J | Director |
Dec 16 '24 |
Sale |
3.32 |
8,000 |
26,569 |
67,241 |
1.21%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):